Bruker Corporation
Every calculator, already run for BRKR
Open the full toolkit →You have the numbers on BRKR. Get the argument.
A written report on which of these readings actually decide the outcome for Bruker Corporation, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
14 analysts covering BRKRAnalyst Price Target Disagreement for Bruker Corporation
Wall Street's bull case implies +14% from the current price; the bear case implies -35%. A 49% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for BRKR
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Bruker Corporation
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digita…
BRKR — frequently asked
Is BRKR a buy right now?
Wall Street's consensus rating on Bruker Corporation is Buy across 14 analysts, with a mean price target of $59.23 (-4% vs. the current $61.39). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is BRKR overvalued?
BRKR trades at — trailing earnings, against a DCF fair value of $22 per share. The current price implies 20% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is BRKR's next earnings date?
Bruker Corporation is next scheduled to report earnings around Nov 3, 2026. A full BRKR research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Bruker Corporation?
Analysts covering Bruker Corporation (BRKR) range from a bear-case target of $40.00 to a bull-case high of $70.00, with a mean consensus target of $59.23 across 13 analysts. The spread of $30.00 (49% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Bruker Corporation against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Bruker Corporation
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full BRKR research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Bruker Corporation, in minutes. 3 free reports included with every account — no credit card required.